Compare Moderna, Inc. (MRNA) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Victoria's Secret & Co — how do they compare? Moderna, Inc. trades at $63.59 (market cap $24.18B), while Victoria's Secret & Co trades at $94.16 (market cap $7.48B). The key difference: Moderna, Inc. is far larger — about 3.2× Victoria's Secret & Co's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | VSXY | |
|---|---|---|
Market Cap | $24.18B | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $99.97 |
52-Week Low | $22.36 | $21.34 |
Enterprise Value | $20.33B | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Victoria's Secret (VSXY) trades at $92.97, down 7.0% on the day but maintains strong technical momentum with bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow projections for 2026. Recent news highlights international expansion success, particularly in China, and data-driven marketing initiatives driving growth.
The stock presents a balanced opportunity with analyst consensus favoring Buy ratings (55.6%) and a $91 price target near current levels. Key risks include competitive pressures in apparel retail and margin volatility, while catalysts include continued international growth and potential earnings surprises in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
